CompletedPhase 1NCT01129180

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

Studying Adult T-cell leukemia/lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Pierluigi Porcu
Principal Investigator
Pierluigi Porcu
Ohio State University
Intervention
azacitidine(drug)
Enrollment
8 enrolled
Eligibility
18 years · All sexes
Timeline
2010 – 2012

Study locations (1)

Collaborators

Millennium Pharmaceuticals, Inc. · Celgene Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01129180 on ClinicalTrials.gov

Other trials for Adult T-cell leukemia/lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Adult T-cell leukemia/lymphoma →

← Back to all trials